The Federal Circuit said an administrative tribunal was justified in invalidating Agilent Technologies Inc. patents relating to a key component of the CRISPR gene-editing system, delivering a win to biotech company Synthego Corp.
An earlier patent application, which Synthego said claimed the same technologies, was sufficiently detailed to serve as invalidating prior art, and there was “no error” in a finding by the Patent Trial and Appeal Board that the application was “enabling,” wrote Judge Sharon Prost in a precedential opinion issued Wednesday by the US Court of Appeals for the Federal Circuit.
The two Agilent patents under the microscope ...
Learn more about Bloomberg Law or Log In to keep reading:
Learn About Bloomberg Law
AI-powered legal analytics, workflow tools and premium legal & business news.
Already a subscriber?
Log in to keep reading or access research tools.